Key result
Hydralazine prevents DOCA-induced hypertension and vascular remodeling, offsetting a ~45% rise in blood pressure.
Why the study?
Structural changes in resistance vessels contribute to long-term maintenance of hypertension, but the time course of these changes during DOCA hypertension and after cessation was not fully characterized.
Does hydralazine prevent structural changes in renal arterioles in a rat model of DOCA-induced hypertension?
Population
Wistar rats undergoing DOCA treatment and post-DOCA period
Comparison
DOCA treatment vs control and DOCA plus hydralazine vs control
Design
Histometric assessment of renal arterioles in a preclinical study
Follow-up
Up to 10 weeks treatment plus 10 weeks post-DOCA
Authors
Loading...
Animal data on resistance vessel remodeling in DOCA hypertension remain hypothesis-generating; human studies needed before clinical relevance.
Does hydralazine prevent structural changes in renal arterioles in a rat model of DOCA-induced hypertension?
Absolute Event Rate: 192% vs 132%
Prevention of hypertension with hydralazine in DOCA-treated rats largely prevents structural changes in renal arterioles, supporting the role of blood pressure in driving these vascular changes.
Vial et al. (1989) studied Hypertension. Deoxycorticosterone acetate (DOCA) and hydralazine vs. Controls was evaluated on Blood pressure. DOCA treatment in Wistar rats increased blood pressure to 192 mmHg compared with 132 mmHg in controls at 10 weeks, while hydralazine prevented both hypertension and structural changes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: